![Jennifer Robinson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jennifer Robinson
Investor Relations Kontakt bei VERVE THERAPEUTICS, INC.
Aktive Positionen von Jennifer Robinson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VERVE THERAPEUTICS, INC. | Investor Relations Kontakt | - | - |
Public Communications Contact | - | - |
Karriereverlauf von Jennifer Robinson
Ehemalige bekannte Positionen von Jennifer Robinson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
DYAX CORP. | Investor Relations Kontakt | 01.10.2011 | 01.04.2016 |
Public Communications Contact | 01.10.2011 | 01.04.2016 | |
RA PHARMACEUTICALS, INC. | Investor Relations Kontakt | - | - |
Public Communications Contact | - | - | |
DECIPHERA PHARMACEUTICALS, INC. | Investor Relations Kontakt | - | - |
Public Communications Contact | - | - | |
ADICET BIO, INC. | Investor Relations Kontakt | 01.06.2018 | - |
Public Communications Contact | 01.06.2018 | - |
Ausbildung von Jennifer Robinson
Dartmouth College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Investor Relations Contact | 5 |
Public Communications Contact | 5 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
VERVE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Dyax Corp.
![]() Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
resTORbio, Inc.
![]() resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Deciphera Pharmaceuticals, Inc.
![]() Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
![]() Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Jennifer Robinson
- Erfahrung